Samsung-backed AI chip startup Rebellions says it plans to pursue an initial public offering in South Korea next year. In comments to CNBC, CEO Sunghyun Park indicates the company is considering a listing venue within South Korea’s main stock markets, leaning toward the KOSPI rather than KOSDAQ. The reports frame the move as part of Rebellions’ broader path to public markets, with the CEO outlining the company’s preference among available exchanges. Details beyond the timing and the contemplated listing board are not provided in the available coverage. Overall, both outlets agree on the core point that Rebellions is targeting an IPO next year in South Korea, while CNBC adds that management currently favors KOSPI as its listing option.
Samsung-backed Rebellions targets IPO in South Korea next year
Samsung-backed AI chip startup Rebellions says it plans to pursue an initial public offering in South Korea next year. In comments to CNBC, CEO Sunghyun Park indicates the company is considering a lis...
- Rebellions is a South Korean AI chip startup backed by Samsung.
- The company targets an IPO in South Korea next year.
- CEO Sunghyun Park says Rebellions is leaning toward listing on KOSPI.
- The CEO indicates KOSDAQ is a secondary option.
- Public-market plans are based on management discussions reported by major outlets.
Sunghyun Park, CEO of Rebellions, told CNBC that the company is leaning toward a listing on the KOSPI over the KOSDAQ.
1 month agoDodgers remove Shohei Ohtani from pitching rotation due to lingering left knee soreness
The Los Angeles Dodgers remove Shohei Ohtani from the pitching rotation as he manages lingering left knee soreness. Mult...
Doug Ford unveils Lake Ontario sign after Trump’s executive order renaming it “Lake America”
Ontario Premier Doug Ford unveils a large “Lake Ontario” sign at a park on the lake’s shores, responding to a U.S. execu...
Walmart settles DOJ opioid lawsuit for $50 million over pharmacy dispensing allegations
Walmart settles a long-running federal lawsuit brought by the U.S. Justice Department over allegations that its pharmaci...